cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2017-6-148-154cardiovascular-727Research ArticleОБЗОРЫREVIEWSНОВЫЕ НАПРАВЛЕНИЯ ФАРМАКОТЕРАПИИ АТЕРОСКЛЕРОЗАNEW DIRECTIONS IN ATHEROSCLEROSIS PHARMACOTHERAPYДутоваС. В.DutovaS. V.

Доктор фармацевтических наук, профессор кафедры фундаментальной медицины и гигиены 

Абакан

СаранчинаЮ. В.SaranchinaYu. V.

Кандидат биологических наук, доцент кафедры фундаментальной медицины и гигиены 

Абакан

july.saran4ina2010@yandex.ruКилинаО. Ю.KilinaO. Yu.

Доктор медицинских наук, директор медико-психолого-социального института 

Абакан

ПольщаН. Г.PolshchaN. G.

Кандидат медицинских наук, зав. кафедрой внутренних болезней 

Абакан

КулаковаТ. С.KulakovaT. S.

Ординатор кафедры внутренних болезней 

Абакан

ХанаринН. В.KhanarinN. V.

Кандидат медицинских наук, доцент кафедры общепрофессиональных дисциплин 

Абакан

ФГБОУ ВО “Хакасский государственный университет им. Н.Ф. Катанова”FSBEI HE N.F. Katanov Khakassky State Medical University201720122017166148154Copyright © Дутова С.В., Саранчина Ю.В., Килина О.Ю., Польща Н.Г., Кулакова Т.С., Ханарин Н.В., 20172017Дутова С.В., Саранчина Ю.В., Килина О.Ю., Польща Н.Г., Кулакова Т.С., Ханарин Н.В.Dutova S.V., Saranchina Y.V., Kilina O.Y., Polshcha N.G., Kulakova T.S., Khanarin N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/727

В обзоре представлена современная информация о возможных мишенях для лекарственных средств специфического патогенетического действия при атеросклерозе. Описаны результаты использования некоторых препаратов в комплексной терапии атеросклеротических поражений сосудов. Приведенные сведения могут быть использованы для направленной разработки антиатеросклеротических лекарственных средств с целью профилактики прогрессирования атеросклеротических поражений сосудов и развития тромбоэмболических осложнений. 

In the review, recent data presented, on possible targets for medications of specific pathogenetic action in atherosclerosis. The results described, of application of some drugs in complex treatment of atherosclerotic vessels lesions. The data can be applied for target development of antiatherosclerotic drugs with the aim of prevented progression of atherosclerosis and thromboembolic complications.

атеросклерозцитокиныферментылекарственные препаратыatherosclerosiscytokinesenzymesmedicationsReferencesKovalenko VN, Talaeva TV, Bratus’ VV. Cholesterol and atherosclerosis: traditional views and modern ideas. Ukrainian Cardiological Journal 2010; 3: 7-35. (in Russ.) Коваленко В. Н., Талаева Т. В., Братусь В. В. Холестерин и атеросклероз: традиционные взгляды и современные представления. Український кардіологічний журнал 2010; 3: 7-35.Kovalenko VN, Talaeva TV, Bratus’ VV. Cholesterol and atherosclerosis: traditional views and modern ideas. Ukrainian Cardiological Journal 2010; 3: 7-35. (in Russ.) Коваленко В. Н., Талаева Т. В., Братусь В. В. Холестерин и атеросклероз: традиционные взгляды и современные представления. Український кардіологічний журнал 2010; 3: 7-35.Jur’eva JeA, Sukhorukov VS, Vozdvizhenskaja ES, Novikova NN. Atherosclerosis: hypotheses and theories. Russian herald of perinatology and pediatrics 2014; 3: 6-16. (in Russ.) Юрьева Э. А., Сухоруков В. С., Воздвиженская Е. С., Новикова Н. Н. Атеросклероз: гипотезы и теории. Российский вестник перинатологии и педиатрии. 2014; 3: 6-16.Jur’eva JeA, Sukhorukov VS, Vozdvizhenskaja ES, Novikova NN. Atherosclerosis: hypotheses and theories. Russian herald of perinatology and pediatrics 2014; 3: 6-16. (in Russ.) Юрьева Э. А., Сухоруков В. С., Воздвиженская Е. С., Новикова Н. Н. Атеросклероз: гипотезы и теории. Российский вестник перинатологии и педиатрии. 2014; 3: 6-16.Kilessa VV. Atherosclerosis in the aspect of recapitulation. Crimean Journal of Experimental and Clinical Medicine. 2012; 2 (3-4): 7-22. (in Russ.) Килесса В. В. Атеросклероз в аспекте рекапитуляции. Крымский журнал экспериментальной и клинической медицины. 2012; 2 (3-4): 17-22.Kilessa VV. Atherosclerosis in the aspect of recapitulation. Crimean Journal of Experimental and Clinical Medicine. 2012; 2 (3-4): 7-22. (in Russ.) Килесса В. В. Атеросклероз в аспекте рекапитуляции. Крымский журнал экспериментальной и клинической медицины. 2012; 2 (3-4): 17-22.Karagodin VP, Bobryshev JuV, Orekhov AN. Inflammation, immunocompetent cells, cytokines — a role in atherogenesis. Pathogenesis 2014; 12 (1): 21-35. (in Russ.) Карагодин В. П., Бобрышев Ю. В., Орехов А. Н. Воспаление, иммунокомпетентные клетки, цитокины — роль в атерогенезе. Патогенез 2014; 12 (1): 21-35.Karagodin VP, Bobryshev JuV, Orekhov AN. Inflammation, immunocompetent cells, cytokines — a role in atherogenesis. Pathogenesis 2014; 12 (1): 21-35. (in Russ.) Карагодин В. П., Бобрышев Ю. В., Орехов А. Н. Воспаление, иммунокомпетентные клетки, цитокины — роль в атерогенезе. Патогенез 2014; 12 (1): 21-35.Bobryshev YV, Ivanova EA, Chistiakov DA, еt al. Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. BioMed Research International 2016; 2016: 1-13.Bobryshev YV, Ivanova EA, Chistiakov DA, еt al. Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. BioMed Research International 2016; 2016: 1-13.Zhao XN, Li YN, Wang YT. Interleukin-4 regulates macrophage polarization via the MAPK signaling pathway to protect against atherosclerosis. Genetics and molecular research 2016; 15 (1): 2-9.Zhao XN, Li YN, Wang YT. Interleukin-4 regulates macrophage polarization via the MAPK signaling pathway to protect against atherosclerosis. Genetics and molecular research 2016; 15 (1): 2-9.Chen Y, Liu W, Wang Y, еt аl. Casein kinase 2 interacting protein-1 regulates M1 and M2 inflammatory macrophage polarization. Cellular signaling 2017; 33: 107-20.Chen Y, Liu W, Wang Y, еt аl. Casein kinase 2 interacting protein-1 regulates M1 and M2 inflammatory macrophage polarization. Cellular signaling 2017; 33: 107-20.Karkhah A, Saadi M, Nouri HR. In silico analyses of heat shock protein 60 and calreticulin to designing a novel vaccine shifting immune response toward T helper 2 in atherosclerosis. Сomputational biology and chemistry 2017; 67: 244-54.Karkhah A, Saadi M, Nouri HR. In silico analyses of heat shock protein 60 and calreticulin to designing a novel vaccine shifting immune response toward T helper 2 in atherosclerosis. Сomputational biology and chemistry 2017; 67: 244-54.Klingenberg R, Lebens M, Hermansson A, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 946-52.Klingenberg R, Lebens M, Hermansson A, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 946-52.Libby P, Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree Players and Layers. Circulation research 2016; 116 (2): 307-11.Libby P, Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree Players and Layers. Circulation research 2016; 116 (2): 307-11.Alekberova ZS, Popkova TV, Nasonov EL. Mycophenolate mofetil and atherosclerosis. Scientific and Practical Rheumatology 2009; 5: 48-51. (in Russ.) Алекберова З. С., Попкова Т. В., Насонов Е. Л. Микофенолата мофетил и атеросклероз. Научно- практическая ревматология 2009; 5: 48-51.Alekberova ZS, Popkova TV, Nasonov EL. Mycophenolate mofetil and atherosclerosis. Scientific and Practical Rheumatology 2009; 5: 48-51. (in Russ.) Алекберова З. С., Попкова Т. В., Насонов Е. Л. Микофенолата мофетил и атеросклероз. Научно- практическая ревматология 2009; 5: 48-51.Maxime N, Sylviane T, Nguyen-Khoa Th, et al. Mycophenolate Mofetil and Rapamycin Induce Apoptosis in the Human Monocytic U937 Cell Line Through Two Different Pathways. Jo cellul biochem 2017; 118 (10): 3480-7.Maxime N, Sylviane T, Nguyen-Khoa Th, et al. Mycophenolate Mofetil and Rapamycin Induce Apoptosis in the Human Monocytic U937 Cell Line Through Two Different Pathways. Jo cellul biochem 2017; 118 (10): 3480-7.Jhun JY, Kwon JE, Kim SY, et al. Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PloS One 2017; 12 (2): 1-14.Jhun JY, Kwon JE, Kim SY, et al. Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PloS One 2017; 12 (2): 1-14.Poljakov LM, Panin LE. High-density lipoproteins and apolipoprotein A-I: regulatory role and new therapeutic strategies for the treatment of atherosclerosis. Аtherosclerosis 2013; 9 (1): 42-53. (in Russ.) Поляков Л. М., Панин Л. Е. Липопротеины высокой плотности и аполипопротеин А-I: регуляторная роль и новые терапевтические стратегии лечения атеросклероза. Атеросклероз 2013; 9 (1): 42-53.Poljakov LM, Panin LE. High-density lipoproteins and apolipoprotein A-I: regulatory role and new therapeutic strategies for the treatment of atherosclerosis. Аtherosclerosis 2013; 9 (1): 42-53. (in Russ.) Поляков Л. М., Панин Л. Е. Липопротеины высокой плотности и аполипопротеин А-I: регуляторная роль и новые терапевтические стратегии лечения атеросклероза. Атеросклероз 2013; 9 (1): 42-53.Tardif JC, Rheaume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8 (2): 372-82.Tardif JC, Rheaume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8 (2): 372-82.Tang M, Fang J. TNF-alpha regulates apoptosis of human vascular smooth muscle cells through gap junctions. Molecular medicine reports 2017; 15(3):1407-11.Tang M, Fang J. TNF-alpha regulates apoptosis of human vascular smooth muscle cells through gap junctions. Molecular medicine reports 2017; 15(3):1407-11.Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry 2008; 54 (1): 24-38.Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry 2008; 54 (1): 24-38.Alekperov JeZ, Nadzharov RN. Modern concepts on the role of inflammation in atherosclerosis. Kardiologiia 2010; 6: 88-91. (in Russ.) Алекперов Э. З., Наджаров Р. Н. Современные концепции о роли воспаления при атеросклерозе. Кардиология 2010; 6: 88-91.Alekperov JeZ, Nadzharov RN. Modern concepts on the role of inflammation in atherosclerosis. Kardiologiia 2010; 6: 88-91. (in Russ.) Алекперов Э. З., Наджаров Р. Н. Современные концепции о роли воспаления при атеросклерозе. Кардиология 2010; 6: 88-91.Bespalova ID, Rjazanceva NV, Kaljuzhin VV, et al. Systemic inflammation in the pathogenesis of metabolic syndrome and associated diseases. Siberian Medical J 2013; 2: 5-9. (in Russ.) Беспалова И. Д., Рязанцева Н. В., Калюжин В. В. и др. Системное воспаление в патогенезе метаболического синдрома и ассоциированных с ним заболеваний. Сибирский медицинский журнал 2013; 2: 5-9.Bespalova ID, Rjazanceva NV, Kaljuzhin VV, et al. Systemic inflammation in the pathogenesis of metabolic syndrome and associated diseases. Siberian Medical J 2013; 2: 5-9. (in Russ.) Беспалова И. Д., Рязанцева Н. В., Калюжин В. В. и др. Системное воспаление в патогенезе метаболического синдрома и ассоциированных с ним заболеваний. Сибирский медицинский журнал 2013; 2: 5-9.Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 2005; 25: 963-76.Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 2005; 25: 963-76.von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation cytokine. Growth factor Rev 2010; 21 (6): 463-9.von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation cytokine. Growth factor Rev 2010; 21 (6): 463-9.Ershova OB, Belova KJu, Novikova IV, et al. The role of cytokines in the development of cardiovascular osteoporosis and osteoporosis (review of the literature). Osteoporosis and osteopathy 2011; 3: 33-5. (in Russ.) Ершова О. Б., Белова К. Ю., Новикова И. В. и др. Роль цитокинов в развитии сердечно-сосудистых заболеваний и остеопороза (обзор литературы). Остеопороз и остеопатии 2011; 3: 33-5.Ershova OB, Belova KJu, Novikova IV, et al. The role of cytokines in the development of cardiovascular osteoporosis and osteoporosis (review of the literature). Osteoporosis and osteopathy 2011; 3: 33-5. (in Russ.) Ершова О. Б., Белова К. Ю., Новикова И. В. и др. Роль цитокинов в развитии сердечно-сосудистых заболеваний и остеопороза (обзор литературы). Остеопороз и остеопатии 2011; 3: 33-5.Arabidze GG. Clinical immunology of atherosclerosis — from theory to practice. Atherosclerosis and dyslipidemia 2013; 1: 4-19. (in Russ.) Арабидзе Г. Г. Клиническая иммунология атеросклероза — от теории к практике. Атеросклероз и дислипидемии 2013; 1: 4-19.Arabidze GG. Clinical immunology of atherosclerosis — from theory to practice. Atherosclerosis and dyslipidemia 2013; 1: 4-19. (in Russ.) Арабидзе Г. Г. Клиническая иммунология атеросклероза — от теории к практике. Атеросклероз и дислипидемии 2013; 1: 4-19.Popa CF, van Der Hoogen N, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.Popa CF, van Der Hoogen N, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.Buono C, Come CE, Stavrakis G, et al. Inluence of interferongamma on the extent and phenotype of diet induced atherosclerosis in the LDLR deicient mouse. Arterioscler hromb Vasc Biol 2003; 23: 454-60.Buono C, Come CE, Stavrakis G, et al. Inluence of interferongamma on the extent and phenotype of diet induced atherosclerosis in the LDLR deicient mouse. Arterioscler hromb Vasc Biol 2003; 23: 454-60.Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-67.Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-67.Kozlov VA. Suppressor cells are the basis of immunopathogenesis of autoimmune diseases. Medical Immunology 2016; 18 (1): 7-15. (in Russ.) Козлов В. А. Клеткисупрессоры — основа иммунопатогенеза аутоиммунных заболеваний. Медицинская иммунология 2016; 18 (1): 7-15.Kozlov VA. Suppressor cells are the basis of immunopathogenesis of autoimmune diseases. Medical Immunology 2016; 18 (1): 7-15. (in Russ.) Козлов В. А. Клеткисупрессоры — основа иммунопатогенеза аутоиммунных заболеваний. Медицинская иммунология 2016; 18 (1): 7-15.Chen S, Shimada K, Zhang W, et al. IL-17A is proatherogenic in hightfat diet-induced and Chlamidia pneumonia infection-accelerated atherosclerosis in mice. J Immunol 2010; 185 (9): 5619-27.Chen S, Shimada K, Zhang W, et al. IL-17A is proatherogenic in hightfat diet-induced and Chlamidia pneumonia infection-accelerated atherosclerosis in mice. J Immunol 2010; 185 (9): 5619-27.Jerdes ShF. Interleukin 17A — a new target of anticytokine therapy of ankylosing spondylitis. Scientific and Practical Rheumatology 2016; 54 (S1): 60-6. (in Russ.) Эрдес Ш. Ф. Интерлейкин 17А — новая мишень антицитокиновой терапии анкилозирующего спондилита. Научно-практическая ревматология 2016; 54 (S1): 60-6.Jerdes ShF. Interleukin 17A — a new target of anticytokine therapy of ankylosing spondylitis. Scientific and Practical Rheumatology 2016; 54 (S1): 60-6. (in Russ.) Эрдес Ш. Ф. Интерлейкин 17А — новая мишень антицитокиновой терапии анкилозирующего спондилита. Научно-практическая ревматология 2016; 54 (S1): 60-6.Cardilo Reis L, Gruber S, Schreier SM. Interleukin 13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. Molecular Medicine 2012; 4: 1072-86.Cardilo Reis L, Gruber S, Schreier SM. Interleukin 13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. Molecular Medicine 2012; 4: 1072-86.Fangying C, Xiaoxiao L, Xiangrong C, et al. Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system. Biochemical and biophysical research communications 2017; 491 (3): 578-86.Fangying C, Xiaoxiao L, Xiangrong C, et al. Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system. Biochemical and biophysical research communications 2017; 491 (3): 578-86.Tufanli O, Akillilar PT, Acosta-Alvear D, et al. Targeting IRE1 with small molecules counteracts progression of atherosclerosis. Proceedings of the national academy of sciences of the united states of America 2017; 114 (8): 1395-404.Tufanli O, Akillilar PT, Acosta-Alvear D, et al. Targeting IRE1 with small molecules counteracts progression of atherosclerosis. Proceedings of the national academy of sciences of the united states of America 2017; 114 (8): 1395-404.Pavlova OV, Moskovtsev AA, Klement’eva TS, et al. Suppression of ribonuclease ERE1 activity - a new approach in the therapy of certain types of oncological diseases. Successes in chemistry and chemical technology 2014; XXVII (9): 76-9. (in Russ.) Павлова О. В., Московцев А. А., Клементьева Т. С. и др. Подавление активности рибонуклеазы IRE1 — новый подход в терапии некоторых видов онкологических заболеваний. Успехи в химии и химической технологии 2014; XXVIII (9): 76-9.Pavlova OV, Moskovtsev AA, Klement’eva TS, et al. Suppression of ribonuclease ERE1 activity - a new approach in the therapy of certain types of oncological diseases. Successes in chemistry and chemical technology 2014; XXVII (9): 76-9. (in Russ.) Павлова О. В., Московцев А. А., Клементьева Т. С. и др. Подавление активности рибонуклеазы IRE1 — новый подход в терапии некоторых видов онкологических заболеваний. Успехи в химии и химической технологии 2014; XXVIII (9): 76-9.Liu H, Cheng WL, Jiang X, et al. Ablation of interferon regulatory factor 3 protects against atherosclerosis in apolipoprotein E-deficient mice. Hypertension 2017; 69 (3): 510-7.Liu H, Cheng WL, Jiang X, et al. Ablation of interferon regulatory factor 3 protects against atherosclerosis in apolipoprotein E-deficient mice. Hypertension 2017; 69 (3): 510-7.Mitsumasa S, Li Y, Takafumi H, et al. Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2017; 265: 283-91.Mitsumasa S, Li Y, Takafumi H, et al. Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2017; 265: 283-91.White CR, Anantharamaiah GM. Cholesterol reduction and macrophage function: role of paraoxonases. Current opinion in lipidology 2017; 28 (5): 397-402.White CR, Anantharamaiah GM. Cholesterol reduction and macrophage function: role of paraoxonases. Current opinion in lipidology 2017; 28 (5): 397-402.Kukharchuk VV, Bazhan SS. Proprotein convertase the family of subtilisin/Kexin type 9 (PCSK9) is a regulator of the expression of receptors of low-density lipoprotein. Atherosclerosis and dyslipidemia 2013; 2 (11): 19-26. (in Russ.) Кухарчук В. В., Бажан С. С. Пропротеин конвертаза субтилизин/кексин типа 9 (PCSK9) — регулятор экспрессии рецепторов липопротеинов низкой плотности. Атеросклероз и дислипидемии 2013; 2 (11): 19-26.Kukharchuk VV, Bazhan SS. Proprotein convertase the family of subtilisin/Kexin type 9 (PCSK9) is a regulator of the expression of receptors of low-density lipoprotein. Atherosclerosis and dyslipidemia 2013; 2 (11): 19-26. (in Russ.) Кухарчук В. В., Бажан С. С. Пропротеин конвертаза субтилизин/кексин типа 9 (PCSK9) — регулятор экспрессии рецепторов липопротеинов низкой плотности. Атеросклероз и дислипидемии 2013; 2 (11): 19-26.Masa-aki K, Nohara Atsushi, Higashikata Toshinori, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis 2017; 265: 225-30.Masa-aki K, Nohara Atsushi, Higashikata Toshinori, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis 2017; 265: 225-30.Kukharchuk VV, Tararak JeM. Atherosclerosis: from A. L. Myasnikov to our days. Cardiologic Herald 2010; 5 (17): 1: 12-20. (in Russ.) Кухарчук В. В., Тарарак Э. М. Атеросклероз: от А. Л. Мясникова до наших дней. Кардиологический вестник 2010; 5 (17): 1: 12-20.Kukharchuk VV, Tararak JeM. Atherosclerosis: from A. L. Myasnikov to our days. Cardiologic Herald 2010; 5 (17): 1: 12-20. (in Russ.) Кухарчук В. В., Тарарак Э. М. Атеросклероз: от А. Л. Мясникова до наших дней. Кардиологический вестник 2010; 5 (17): 1: 12-20.Harvey D, White DSc, Claes Held, et al. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med 2014; 370:1702-11.Harvey D, White DSc, Claes Held, et al. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med 2014; 370:1702-11.Kyaw T, Tipping P, Bobik A, et al. Opposing roles of B lymphocyte subsets in atherosclerosis. Autoimmunity 2017; 50: 1: 52-6.Kyaw T, Tipping P, Bobik A, et al. Opposing roles of B lymphocyte subsets in atherosclerosis. Autoimmunity 2017; 50: 1: 52-6.Wennink Jos WH, Liu Yanna, Makinen Petri I, et al. Macrophage selective photodynamic therapy by meta-tetra(hydroxyphenyl) chlorin loaded polymeric micelles: A possible treatment for cardiovascular diseases. Eur J Pharmaceutical Sciences 2017; 107: 112-25.Wennink Jos WH, Liu Yanna, Makinen Petri I, et al. Macrophage selective photodynamic therapy by meta-tetra(hydroxyphenyl) chlorin loaded polymeric micelles: A possible treatment for cardiovascular diseases. Eur J Pharmaceutical Sciences 2017; 107: 112-25.Xue F, Nie X, Shi J, et al. Quercetin Inhibits LPS-Induced Inflammation and ox-LDLInduced Lipid Deposition. Front Pharmacol 2017; 8: 40.Xue F, Nie X, Shi J, et al. Quercetin Inhibits LPS-Induced Inflammation and ox-LDLInduced Lipid Deposition. Front Pharmacol 2017; 8: 40.Bieganska-Hensoldt S, Rosolowska-Huszcz D. Polyphenols in preventing endothelial dysfunction. Postepy higieny i medycyny doswiadczalnej 2017; 71: 227-35.Bieganska-Hensoldt S, Rosolowska-Huszcz D. Polyphenols in preventing endothelial dysfunction. Postepy higieny i medycyny doswiadczalnej 2017; 71: 227-35.Alaarg Amr, Senders Max L, Varela-Moreira Aida, et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Controll Release 2017; 262: 47-57.Alaarg Amr, Senders Max L, Varela-Moreira Aida, et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Controll Release 2017; 262: 47-57.

The authors declare that there are no conflicts of interest present.